Drug news
FDA approves Secuado transdermal patch formulation for the treatment of adults with schizophrenia. Noven Pharma
Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., has announced the FDA approved Secuado (asenapine) transdermal system, the first-and-only transdermal patch formulation for the treatment of adults with schizophrenia.
Secuado is administered once per day via a transdermal drug delivery system that provides sustained concentrations of antipsychotic asenapine during the recommended wear time of 24 hours.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins